Skip to main content
Fig. 3 | BMC Bioinformatics

Fig. 3

From: DNAfusion: an R/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies

Fig. 3

DNAfusion and AVENIO results of the validation cohort. a Number of patients with detectable and undetectable EML4-ALK in liquid biopsies from the Madsen cohort, determined with either AVENIO or DNAfusion (n = 24). b Number of patients with detectable and undetectable EML4-ALK in liquid biopsies from the Clement cohort, determined with either AVENIO or DNAfusion (n = 24). c The EML4 breakpoint read depth in patients positive for EML4-ALK in both AVENIO and DNAfusion (n = 6) or only DNAfusion (n = 8). Median and IQR are indicated. D EML4-ALK positivity for AVENIO and DNAfusion for the Madsen cohort patients before the first line (n = 14) or second/third line (n = 10) ALK treatment. e Number of EML4 clipped reads detected with either AVENIO or DNAfusion throughout the follow-up of Madsen_18 and Madsen_15. *P < 0.05; **P < 0.01

Back to article page

BMC Bioinformatics

ISSN: 1471-2105

Contact us